These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 28196724

  • 21. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z, Nazir J, McCrea C, Berling M, Fatoye F, Ramos B, Wagg A.
    J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
    [Abstract] [Full Text] [Related]

  • 22. Long-term persistence with mirabegron in a real-world clinical setting.
    Wada N, Watanabe M, Banjo H, Tsuchida M, Hori J, Tamaki G, Azumi M, Kita M, Kakizaki H.
    Int J Urol; 2018 May; 25(5):501-506. PubMed ID: 29651798
    [Abstract] [Full Text] [Related]

  • 23. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, Drake MJ.
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [Abstract] [Full Text] [Related]

  • 24. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
    Mandpe P, Prabhakar B, Shende P.
    Curr Drug Metab; 2020 Dec; 21(2):79-88. PubMed ID: 32334500
    [Abstract] [Full Text] [Related]

  • 25. [A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions].
    Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, Saez M, Coll-de Tuero G, Sánchez L.
    Semergen; 2017 Dec; 43(4):277-288. PubMed ID: 27371430
    [Abstract] [Full Text] [Related]

  • 26. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
    Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE.
    Int J Clin Pract; 2013 Jul; 67(7):619-32. PubMed ID: 23692526
    [Abstract] [Full Text] [Related]

  • 27. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY.
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [Abstract] [Full Text] [Related]

  • 28. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC.
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [Abstract] [Full Text] [Related]

  • 29. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER.
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [Abstract] [Full Text] [Related]

  • 30. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR.
    Health Qual Life Outcomes; 2018 Apr 19; 16(1):69. PubMed ID: 29673355
    [Abstract] [Full Text] [Related]

  • 31. Drug therapy for an overactive bladder.
    Thiagamoorthy G, Cardozo L, Srikrishna S.
    Womens Health (Lond); 2015 Jul 19; 11(4):445-8. PubMed ID: 26238677
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E.
    Eur Urol; 2019 Dec 19; 76(6):767-779. PubMed ID: 31416636
    [Abstract] [Full Text] [Related]

  • 33. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K.
    Low Urin Tract Symptoms; 2018 May 19; 10(2):148-152. PubMed ID: 27911988
    [Abstract] [Full Text] [Related]

  • 34. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
    Aballéa S, Maman K, Thokagevistk K, Nazir J, Odeyemi IA, Hakimi Z, Garnham A, Toumi M.
    Clin Drug Investig; 2015 Feb 19; 35(2):83-93. PubMed ID: 25491433
    [Abstract] [Full Text] [Related]

  • 35. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y, Kato D, Tabuchi H, Kuroishi K.
    Low Urin Tract Symptoms; 2018 May 19; 10(2):122-130. PubMed ID: 27860325
    [Abstract] [Full Text] [Related]

  • 36. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC, Kuo HC.
    J Formos Med Assoc; 2019 Jan 19; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
    Vonesh E, Gooch KL, Khangulov V, Schermer CR, Johnston KM, Szabo SM, Rumsfeld JS.
    PLoS One; 2018 Jan 19; 13(10):e0205640. PubMed ID: 30325968
    [Abstract] [Full Text] [Related]

  • 38. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
    Krunal Vishavadia KV, Sandip Solanki SS, Hiren Prajapati HP, Madhu Sharma MS.
    Urologiia; 2023 May 19; (2):66-72. PubMed ID: 37401707
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
    Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group.
    Drug Saf; 2021 Aug 19; 44(8):899-915. PubMed ID: 34236595
    [Abstract] [Full Text] [Related]

  • 40. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
    Blais AS, Nadeau G, Moore K, Genois L, Bolduc S.
    Eur Urol; 2016 Jul 19; 70(1):9-13. PubMed ID: 26876327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.